Showing results (151-160 of 208) with videos related to
Sort By:
Pageof 21
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trialMarie Véron, Sylvie Chevret, Jean-Jacques Grob, et al.The Lancet. Oncology|October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic MelanomaReinhard Dummer, Georgina V Long, Caroline Robert, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced MelanomaGeorgina V Long, James Larkin, Dirk Schadendorf, et al.European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsDirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.Cancer|October 23, 2019
Quality-of-life assessment in French patients with metastatic melanoma in real lifeMarguerite Kandel, Stéphane Dalle, Aurélie Bardet, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2025
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid TumorsOliver Bechter, Carmen Loquai, Stephane Champiat, et al.Current Oncology (Toronto, Ont.)|December 22, 2022
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in FranceMarguerite Kandel, Aurélie Bardet, Stéphane Dalle, et al.Cancer Research Communications|February 3, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic MelanomaEva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu, et al.European Journal of Cancer (Oxford, England : 1990)|December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumorsFlorentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.Pageof 21